← All trials
NCT04287660
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2017
- Primary completion
- Jan 31, 2022
- Completion date
- Jan 31, 2024
- First posted
- Feb 27, 2020
- Last posted
- Feb 27, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Soochow UniversityLead sponsor
- Jiangnan UniversityCollaborator
- Changshu First People's HospitalCollaborator
- Huai'an Second People's HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Jiangyin People's HospitalCollaborator
- Jingjiang People's HospitalCollaborator
- Bengbu Medical CollegeCollaborator
- Soochow UniversityCollaborator
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdCollaborator
- Soochow UniversityOverall official - principal investigator
- Kunming Medical UniversityCollaborator
- Zhangjiagang First People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.